Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s ...
technologynetworks10h
Gluing Two Proteins Together Drives Cancer Cells To Self-Destruct
Stanford Medicine researchers discovered a method to induce cancer cell death by manipulating proteins involved in apoptosis.
Marker Therapeutics price target raised to $19 from $11 at Ladenburg
Ladenburg analyst Aydin Huseynov raised the firm’s price target on Marker Therapeutics (MRKR) to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing ...
Rolling Out2d
Lymphoma’s impact on Black men’s health
Lymphoma, a cancer of the immune system, is silently ravaging the health of Black men across America. This insidious disease, ...
3 Promising ASX Penny Stocks With Market Caps Over A$10M
The Australian market remained flat over the last week, but it has seen a 22% rise in the past 12 months, with earnings forecasted to grow by 12% annually. For investors willing to explore beyond ...
BioWorld2d
Chinese researchers disclose IRAK-4 degradation inducers for treatment of DLBCL
A patent from Nanjing Mingde New Drug Research Co. Ltd. and Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. details the identification of salts of interleukin-1 receptor-associated kinase 4 (IRAK-4) ...
AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces
Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...
AbbVie Falters Despite Progress in Lymphoma Treatment
AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...
Goldman Sachs: Pfizer Inc. (NYSE:PFE) Is A Stock With High Consensus ROE
As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.